UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON,Washington, D.C. 20549

 

FORM 10-Q


(Mark one)

[X] QUARTERLY REPORT PURSUANT TO SECTIONQuarterly Report Under Section 13 ORor 15(d) OF THE SECURITIES EXCHANGE ACT OFof the Securities Exchange Act of 1934

For the Quarterly Period Ended December 31, 2017June 30, 2020

ORCommission File No. 000-55018


[ ] TRANSITION REPORT PURSUANT TO SECTIONTransition Report pursuant to Section 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OFor 15(d) of the Securities Exchange Act of 1934

For the transition period from _________________to


Commission File Number: 000-55018________________ to ______________

 

Holly Brothers Pictures, Inc.RAPID THERAPEUTIC SCIENCE

LABORATORIES, INC.

(Exact nameName of registrantRegistrant as specified in its charter)charter)


Nevada

 

46-2111820

(State or Other Jurisdictionother jurisdiction

(I.R.S. Employer

of Incorporation or Organization)

Identification No.)


8221 E. Washington Street, Chagrin Falls, OHincorporation)

 

44023(IRS Employer

Identification Number)

5580 Peterson Ln., Suite 200

Dallas, TX

75240

(Address of principal

executive offices)

(Zip Code)zip code)


(440) 543-4645(800) 497-6059

(Registrant’s telephone number, including area code)


Indicate by check mark whether the registrantRegistrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantRegistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesYes: [X] NoNo: [  ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesYes: [X] No: [  ]  No [  ] Not Applicable


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company definedor an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one).Act.


Large accelerated filer [  ]     Accelerated filer [  ]     Non-accelerated filer [X]     Smaller reporting company [X]     Emerging growth company [  ]

 

Accelerated filer [  ]

Non-accelerated filer [  ]

Smaller Reporting Company [X]

(Do not check if a smaller reporting company)

Emerging Growth Company [  ]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]


There were 2,865,172The number of shares outstanding of Common Stock, outstandingpar value $0.001 per share, as of January 23, 2018.



August 13, 2020 was 164,278,334 shares.




Table of ContentsRAPID THERAPEUTIC SCIENCE LABORATORIES, INC.


(formerly, Holly Brothers Pictures, Inc.)

Index to FormFORM 10-Q

For the Quarterly Period Ended December 31, 2017June 30, 2020



INDEX

Page

PART II. FINANCIAL INFORMATION

Financial Information

3

 

 

ITEMItem 1.

Financial Statements

3

Unaudited Condensed Interim Balance Sheets as of December 31, 2017 and March 31, 2017

3

    Consolidated Balance Sheets as of  June 30, 2020 (Unaudited) and

         March 31, 2020

3

Unaudited Condensed Interim StatementConsolidated Statements of Operations for the three and nine months ended December 31, 2017

         June 30, 2020 and December 31, 20162019 (Unaudited)

4

   

Unaudited Condensed InterimConsolidated Statements of Cash FlowsStockholders’ Deficit for the Ninethree months

         ended December 31, 2017June 30, 2020 and December 31, 20162019 (Unaudited)

5

    

Notes toConsolidated Statements of Cash Flows for the Condensed Interim Financial Statementsthree months ended

         June 30, 2020 and 2019 (Unaudited)

6

    Notes to Consolidated Financial Statements (Unaudited)

7

 

 

ITEMItem 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

8

13

ITEMItem 3.

Quantitative and Qualitative Disclosures About Market Risk

14

17

ITEM 4T.

Item 4. Controls and Procedures

14

PART II

Other Information

17

 

 

PART II. OTHER INFORMATION

 

ITEM 1.

Legal Proceedings

17

 

 

ITEM 1A.Item 1. Legal Proceedings

Risk Factors

17

18

ITEM 2.Item 1A. Risk Factors

18

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

17

ITEM 3.

Defaults Upon Senior Securities

17

ITEM 4.

Submission of Matters to a Vote of Security Holders

17

ITEM 5.

Other Information

17

ITEM 6.

Exhibits

18

SIGNATURESItem 3. Defaults Upon Senior Securities

19

Item 4. Mine Safety Disclosures

19

Item 5. Other Information

19

Item 6. Exhibits

19

Signature

20













2


PartPART I. Financial InformationFINANCIAL INFORMATION


ItemITEM 1. Financial StatementsFINANCIAL STATEMENTS

 

RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(formerly, Holly Brothers Pictures,  Inc.)

(Formerly PowerMedChairs)

CondensedConsolidated Balance Sheets

(Unaudited)

 

June 30, 2020

 

March 31, 2020

Assets

(unaudited)

 

 

Current assets:

 

 

 

 Cash

$

213,123

 

$

136,215

 Inventory

 

28,619

 

 

5,873

   Total current assets

 

241,742

 

 

142,088

 

 

 

 

 

 

Intangible assets:

 

 

 

 

 

 Sublicense agreement, net of accumulated amortization of $62,500

   and $37,500

 

277,500

 

 

302,500

 

 

 

 

 

 

Total assets

$

519,242

 

$

444,588

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 Accounts payable - other

$

83,426

 

$

64,577

 Equity subscription payable

 

90,000

 

 

90,000

 Contract liabilities

 

-

 

 

32,000

 Notes payable - related party

 

23,350

 

 

23,350

 Notes payable - other

 

890,233

 

 

883,185

 Accrued interest payable

 

423,321

 

 

400,720

 Derivative liability, at fair value

 

44,952

 

 

-

   Total current liabilities

 

1,555,282

 

 

1,493,832

 

 

 

 

 

 

Other liabilities:

 

 

 

 

 

 Convertible notes payable

 

315,240

 

 

315,240

Total liabilities

 

1,870,522

 

 

1,809,072

 

 

 

 

 

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ deficit:

 

 

 

 

 

 Preferred stock, no par value per share, 100,000,000 shares

   authorized, no shares issued and outstanding

 

-

 

 

-

 Common stock, $.001 par value per share, 750,000,000 and

   200,000,000 authorized, 161,874,334 and 159,556,000 shares

   issued and outstanding

 

161,874

 

 

159,556

 Additional paid in capital

 

2,991,984

 

 

2,414,718

 Accumulated deficit

 

(4,167,799)

 

 

(3,601,419)

 Treasury stock

 

(337,339)

 

 

(337,339)

   Total stockholders’ deficit

 

(1,351,280)

 

 

(1,364,484)

 

 

 

 

 

 

Total liabilities and stockholders’ deficit

$

519,242

 

$

444,588



 

 

December 31,

2017

 

March 31,

2017

 

 

 

 

 

ASSETS

 

 

 

 

Current assets:

 

 

 

 

 

  Cash and cash equivalents

 

$

5,382

 

$

7,395

 

  Prepaid expense

 

 

-

 

 

-

 

 

    Total current assets

 

 

5,382

 

 

7,395

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

5,382

 

$

7,395

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

  Accounts payable

 

$

-

 

 

300

 

  Due to related party

 

 

-

 

 

30,000

 

 

    Total current liabilities

 

 

-

 

 

30,300

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

  Common stock, $0.001 par value, 200,000,000 shares

    authorized, 2,865,172 and 2,710,000 issued and outstanding as

    of 12/31/2017 and 3/31/2017, respectively

 

 

2,865

 

 

2,710

 

  Additional paid-in capital

 

 

94,310

 

 

49,465

 

  Retained deficit

 

 

(91,793)

 

 

(75,080)

 

 

    Total stockholders’ equity

 

 

5,382

 

 

(22,905)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 

$

5,382

 

$

7,395









TheSee accompanying notes are an integral part of these condensedto unaudited consolidated financial statements.




3



RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(formerly, Holly Brothers Pictures,  Inc.)

(Formerly PowerMedChairs)

CondensedConsolidated Statements of Operations

(Unaudited)


 

Three Months Ended June 30,

 

2020

 

2019

 

 

 

 

Revenues

$

129,287

 

$

-

Costs of goods sold

 

18,556

 

 

-

   Gross profit

 

110,731

 

 

-

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 General and administrative

 

629,510

 

 

22,974

 Amortization expense

 

25,000

 

 

-

   Total operating expenses

 

654,510

 

 

22,974

 

 

 

 

 

 

Other (expense):

 

 

 

 

 

 Interest expense

 

(22,601)

 

 

(46,099)

   Total other income (expense)

 

(22,601)

 

 

(46,099)

 

 

 

 

 

 

Net loss before income taxes

 

(566,380)

 

 

(69,073)

Income taxes

 

-

 

 

-

 

 

 

 

 

 

   Net loss

$

(566,380)

 

$

(69,073)

 

 

 

 

 

 

Net loss per share, basic and diluted

$

(0.00)

 

$

(0.06)

 

 

 

 

 

 

Weighted average shares outstanding, basic and diluted

 

160,447,978

 

 

1,204,000


 

 

For the three

months ended

December 31,

2017

 

For the three

months ended

December 31,

2016

 

For the nine

months ended

December 31,

2017

 

For the nine

months ended

December 31,

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

-

 

$

-

 

$

-

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

  General & administrative

 

 

5,399

 

 

2,800

 

 

16,713

 

 

12,846

    Total expenses

 

 

5,399

 

 

2,800

 

 

16,713

 

 

12,846

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(5,399)

 

 

(2,800)

 

 

(16,713)

 

 

(12,846)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (Loss)

 

$

(5,399)

 

$

(2,800)

 

$

(16,713)

 

$

(12,846)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of

  common shares outstanding- basic

 

 

2,733,613

 

 

2,710,000

 

 

2,717,900

 

 

2,710,000

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share

 

$

(0.00)

 

$

(0.00)

 

$

(0.01)

 

$

(0.00)





















TheSee accompanying notes are an integral part of these condensedto unaudited consolidated financial statements.




4



RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(formerly, Holly Brothers Pictures,  Inc.)

Consolidated Statements of Stockholders’ Deficit

(Unaudited)

 

 

 

Additional

 

 

 

 

 

Total

 

Common Stock

 

Paid-in

 

Accumulated

 

Treasury

 

Stockholders'

 

Shares

Amount

 

Capital

 

Deficit

 

Stock

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2020

159,556,000

$

159,556

 

$

2,414,718

 

$

(3,601,419)

 

$

(337,339)

 

$

(1,364,484)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Private sales of common stock

960,000

 

960

 

 

239,040

 

 

-

 

 

-

 

 

240,000

 Stock compensation expense

1,358,334

 

1,358

 

 

338,226

 

 

-

 

 

-

 

 

339,584

 Net loss

-

 

-

 

 

-

 

 

(566,380)

 

 

-

 

 

(566,380)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

161,874,334

 

161,874

 

 

2,991,984

 

 

(4,167,799)

 

 

(337,339)

 

 

(1,351,280)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2019

1,204,000

 

1,204

 

 

144,477

 

 

(2,976,835)

 

 

(337,339)

 

 

(3,168,493)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense

-

 

-

 

 

10,750

 

 

-

 

 

-

 

 

10,750

Net loss

-

 

-

 

 

-

 

 

(69,073)

 

 

-

 

 

(69,073)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2019

1,204,000

$

1,204

 

$

155,227

 

$

(3,045,908)

 

$

(337,339)

 

$

(3,226,816)

See accompanying notes to unaudited consolidated financial statements.


5


RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(Formerly PowerMedChairs)formerly, Holly Brothers Pictures,  Inc.)

CondensedConsolidated Statements of Cash Flows

(Unaudited)


 

Three Months Ended

June 30,

 

2020

 

2019

Cash flows from operating activities:

 

 

 

 Net loss

$

(566,380)

 

$

(69,073)

 Adjustments to reconcile net loss to net

   cash provided by (used in) operations

 

 

 

 

 

     Stock compensation expense

 

339,584

 

 

10,750

     Amortization expense

 

25,000

 

 

-

     Inventory

 

(22,746)

 

 

-

     Accounts payable

 

18,849

 

 

5,356

     Accrued interest payable

 

22,601

 

 

46,099

     Other, net

 

(32,000)

 

 

-

       Net cash flows used in operating activities

 

(215,092)

 

 

(6,868)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

   Issuance of notes payable to related parties

 

52,000

 

 

8,000

   Private sales of common stock

 

240,000

 

 

-

       Net cash flows provided by financing activities

 

292,000

 

 

8,000

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

76,908

 

 

1,132

Cash and cash equivalents at beginning of period

 

136,215

 

 

1,334

 

 

 

 

 

 

       Cash and cash equivalents at end of period

$

213,123

 

$

2,466

 

 

 

 

 

 

Supplemental cash flow data:

 

 

 

 

 

   Cash paid for interest

$

-

 

$

-

   Cash paid for income taxes

 

-

 

 

-

 

 

 

 

 

 

Supplemental Non-cash financing activities:

 

 

 

 

 

   Debt discount on convertible notes payable

$

(44,952)

 

$

-

   Derivative liabilities

 

44,952

 

 

-


 

For the nine months

ended

December 31, 2017

 

For the nine months

ended

December 31, 2016

 

 

 

 

OPERATING ACTIVITIES

 

 

 

Net loss

$

(16,713)

 

$

(12,846)

Adjustment to reconcile net loss to net cash

 

 

 

 

 

  used by operating activities:

 

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

  Accounts payable

 

(300)

 

 

(527)

Cash (used) by operating activities

 

(17,013)

 

 

(13,373)

 

 

 

 

 

 

FINANCING ACTIVITIES

 

 

 

 

 

  Proceeds from related party debt

 

15,000

 

 

10,000

Net cash provided by financing activities

 

15,000

 

 

10,000

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH

 

(2,013)

 

 

(3,373)

CASH - BEGINNING OF THE PERIOD

 

7,395

 

 

9,238

CASH - END OF THE PERIOD

$

5,382

 

$

5,865

 

 

 

 

 

 

Supplemental Disclosures:

 

 

 

 

 

Interest paid

 

-

 

 

-

Income taxes paid

 

-

 

 

-

 

 

 

 

 

 

Non-Cash investing and financing transactions:

 

 

 

 

 

Stock issued to settle debt

$

45,000

 

$

-



 












TheSee accompanying notes are an integral part of these condensedto unaudited consolidated financial statements.




6



RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(formerly, Holly Brothers Pictures,  Inc.)

(Formerly PowerMedChairs)

Notes to the Consolidated Financial Statements

(Unaudited)

(1)Condensed Interim Financial Statements

December 31,

The Company - Rapid Therapeutic Science Laboratories, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 22, 2013, originally under the name of PowerMedChairs.  On June 2, 2017, the Company changed its name to Holly Brothers Pictures, Inc.  On February 1, 2018, the Company acquired 100% of the equity interests in Power Blockchain, LLC (“Power Blockchain”) through an exchange agreement in a transaction that resulted in the transition to a planned new business of mining crypto-currency.  Effective November 15, 2019, the Company exited from that business and adopted a new business strategy focused on developing potential commercial opportunities which will involve the rapid application of therapeutics using inhaler technology that the Company has sublicensed from a third party as a result of the execution of a sublicense agreement with the sublicensor on that date (see Note 4).  In conjunction with the adoption of the new business strategy, the Company changed its name to Rapid Therapeutic Science Laboratories, Inc., effective January 13, 2020.  At that time, the Company also commenced online sales of its inhaler products.

(Unaudited)



NOTE 1Interim Financial Information - CONDENSED INTERIM FINANCIAL STATEMENTS


The accompanying consolidated financial statements have been prepared by the Company, without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December 31, 2017 and for all periods presented have been made.


Certain information and footnote disclosures normally included in financial statements preparedaudit, in accordance with accounting principles generally accepted in the UnitedUnites States of America have been condensed or omitted. It is suggested that these condensedfor interim financial statements be read in conjunction withinformation and pursuant to the financial statementsrules and notes thereto included in the Company's March 31, 2017 audited financial statements. The results of operations for the period ended December 31, 2017 are not necessarily indicativeregulations of the operating results for the full year.


Basis of Presentation

Securities and Exchange Commission (“SEC”).  In the opinion of management, the accompanying balance sheets and related interimthese consolidated financial statements of income, cash flows, and stockholders' equity includecontain all adjustments, consisting only of normal recurring items,adjustments, necessary to fairly state the financial position of the Company as of June 30, 2020, the results of its operations for their fair presentationthe three month periods ended June 30, 2020 and 2019, the changes in its stockholder’s deficit for the three month periods ended June 30, 2020 and 2019, and cash flows for the three month periods ended June 30, 2020 and 2019. These financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the SEC on June 29, 2020.

Impact of COVID-19 Pandemic on Consolidated Financial Statements. The outbreak of the 2019 novel coronavirus disease (“COVID-19”), which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies. Decreased demand for our products caused by COVID-19 could have a material adverse effect on our results of operations. Separately, economic recessions, including those brought on by the COVID-19 outbreak may have a negative effect on the demand for our products and our operating results. The range of possible impacts on the Company’s business from the coronavirus pandemic could include: (i) changing demand for the Company’s products; (ii) rising bottlenecks in the Company’s supply chain; and (iii) increasing contraction in the capital markets.  At this time, the Company believes that it is premature to determine the potential impact on the Company’s business prospects from these or any other factors that may be related to the coronavirus pandemic.

(2)Summary of Significant Accounting Policies

Basis of Accounting - The basis is United States generally accepted accounting principles. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Power Blockchain, which is presently inactive.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

Cash and Cash Equivalents - The Company considers all short-term investments with a maturity of three months or less at the date of purchase to be cash equivalents.


7


Earnings per Share - The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares issued and outstanding during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first year for any potentially dilutive debt or equity. The Company has not issued any options or warrants or similar securities that are presently exercisable.

Revenue recognition - We account for revenue from contracts with customers in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)."  The unit of account in Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided at a point in time or over a period of time. Topic 606 requires that a contract’s transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when (point in time) or as (over time) the performance obligation is satisfied.

Inventory - Inventory as of June 30, 2020, consists of inhalers and related products and supplies delivered to a location near the Company’s offices, and held for sale to wholesale or retail customers.  Inventory is stated at the lower of weighted average cost or market.

Intangible Assets - The Company amortizes the costs of any renewable license or sub-license agreements over the contractual terms of such renewable agreements.  For any license or sub-license agreements which do not require any renewal payments to be made, the Company performs periodic assessments in order to determine whether there has been any impairment in the carrying value of such intangible assets (see Note 4).

Income Taxes - The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements. A valuation allowance is provided for the amount of deferred assets that, based on available evidence, are not expected to be realized.

Use of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management's estimates and assumptions.


Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K Annual Report.



NOTE 2 - GOING CONCERN


These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of December 31, 2017, the Company has not recognized any revenues and has accumulated operating losses of approximately $91,793 since inception. The Company's ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company's products, to provide financing for marketing and promotion, to secure additional property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations.


These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.





Holly Brothers Pictures, Inc.

(Formerly PowerMedChairs)

Notes to the Condensed Interim Financial Statements

December 31, 2017

(Unaudited)



NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES


Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenuesrevenue and expenses during the reporting period. Actual

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events.  Accordingly, the actual results could differ significantly from those estimates.


RecentFair Value of Financial Instruments - Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as further noted below.

Level 1:The preferred inputs to valuation efforts are “quoted prices in active markets for identical assets or liabilities,” with the caveat that the reporting entity must have access to that market. Information at this level is based on direct observations of transactions involving the same assets and liabilities, not assumptions, and thus offers superior reliability. However, relatively few items, especially physical assets, actually trade in active markets. 

Level 2:FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To  


8


deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations.

Level 3:If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “unobservable,” and limits their use by saying they “shall be used to measure fair value to the extent that observable inputs are not available.” This category allows “for situations in which there is little, if any, market activity for the asset or liability at the measurement date”. Earlier in the standard, FASB explains that “observable inputs” are gathered from sources other than the reporting company and that they are expected to reflect assumptions made by market participants. 

Recently Issued Accounting Pronouncements - In the three months ended June 30, 2020, the Financial Accounting Standards Board issued several new Accounting Standards Updates which the Company believes will have no material impact to the Company.

The Company's management

Subsequent Events - Management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements and does not believe that any of these pronouncements will have a material impact on the Company's financial position and results of operations.



NOTE 4 - RELATED PARTY TRANSACTIONS


On January 20, 2016, $10,000 was loaned to the Company by a shareholder. An additional $10,000 was loaned on August 22, 2016, $10,000 on March 24, 2017, $5,000 on July 13, 2017, $5,000 on October 26, 2017 and $5,000 on December 16, 2017. These loans bore no interest and were due upon demand. As the Company lacked adequate cash to repay these debts, it was mutually agreed on December 18, 2017 to settle this $45,000 debt in exchange for the issuance of 155,172 restricted unregistered shares of common stock.



NOTE 5 - SUBSEQUENT EVENTS


The Company has evaluated subsequent events occurring in the period from December 31, 2017June 30, 2020 through the date the financial statements were issued, to determine if disclosure in this report is warranted (see Note 9).

(3)Going Concern

The Company's consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has generated minimal revenues and has suffered recurring losses totaling $4,167,799 since inception. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing.

In order to obtain the necessary capital to sustain operations, Management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings. There can be no assurances, however, that the Company will be successful in obtaining such additional financing, or that such financing will be available on favorable terms, if at all. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.

(4)Intangible Assets

Effective November 15, 2019, the Company entered into a sublicense agreement with Texas MDI, Inc. (“TMDI”), a Texas corporation, (the "Agreement") granting the Company access to certain technology regarding the RxoidTM metered dose inhaler that TMDI has licensed from a third party. In conjunction with execution of the Agreement, the Company simultaneously issued a total of 140,000,000 shares of its Common Stock to TMDI, in consideration of the sublicense rights granted to the Company in this transaction. Such rights were transferred as a result of extensive third party negotiations between the Company and TMDI and have been recorded as the acquisition of an intangible asset in the amount of $140,000, based on the par value of the shares issued.

During the term of the Agreement, the Company is required to reimburse TMDI to the extent that TMDI is required to make any payments to the licensor, pursuant to its license agreement with a third party.  Accordingly, the Company has an obligation to reimburse TMDI in the amount of $200,000 as a license fee covering the first two years of the Agreement. The Company has partially satisfied this obligation by making an equipment purchase on behalf of the licensor in the amount of $135,000, and has agreed to pay the remaining license fee of $65,000 in cash within a 24 month period (for which, the Company has recorded a liability of $44,925 for the unpaid portion of this amount in accounts payable as of June 30, 2020). The Company has recorded the entire $200,000 license fee as an intangible asset and is amortizing such expense on a straight-line basis over a 24 month period (of which, $25,000 was amortized in the three month period ended June 30, 2020).


9


(5)Notes Payable

As of June 30, 2020 and March 31, 2020, the Company had the following note payable obligations:

 

 

June 30,

 

March 31,

 

 

2020

 

2020

Convertible promissory notes issued to two accredited investors, maturing in 1 to 5 years, accruing interest at 5% per annum, convertible into common stock at $0.05 per share.

 

$

300,000

 

$

300,000

 

 

 

 

 

 

 

Convertible promissory notes issued to former owners in acquisition of Power Blockchain, accruing interest at 5% per annum, principal repayments originally due in four equal installments on 2nd, 3rd, 4th and 5th anniversaries, convertible into common stock at $0.13 per share, with final maturity on February 1, 2023.

 

 

165,240

 

 

165,240

 

 

 

 

 

 

 

Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%.  Amended on November 15, 2019, to mature in one year and to be convertible into common stock at $0.05 per share.

 

 

756,535

 

 

756,535

 

 

 

 

 

 

 

Convertible note issued to an accredited investor on June 30, 2020, net of unamortized debt discount of $44,952 (see further discussion below)

 

 

7,048

 

 

-

 

 

 

 

 

 

 

   Total notes payable

 

$

1,228,823

 

$

1,221,775

Future maturities of notes payable as of June 30, 2020 are as follows:

Year ending June 30, 2021

 

$

913,583

Year ending June 30, 2022

 

 

-

Year ending June 30, 2023

 

 

165,240

Year ending June 30, 2024

 

 

150,000

Year ending June 30, 2025

 

 

-

 

 

$

1,228,823

On June 30, 2020, the Company entered into a Securities Purchase Agreement with an accredited investor (the “Buyer”) with respect to a Convertible Promissory Note (the “Note”) issued by the Company to the Buyer in the amount of $55,000. The Note has a maturity date of one year after the date of issuance and bears interest at a rate of 12% per annum, which is not due until maturity.  At the option of the Buyer, the Note may be converted into shares of the Company’s common stock, beginning one hundred eighty (180) days following the date of issuance. Under this option, the conversion price shall be subject to a discount of 42%, based on the average of the three (3) lowest closing bid prices for the Common Stock during the prior fifteen (15) trading day period. The Buyer will be limited to convert no more than 4.99% of the issued and hasoutstanding Common Stock at time of conversion at any one time. The Company determined that the conversion feature of the Note required the recognition of a derivative liability upon issuance. As of June 30, 2020, the Company calculated the fair value of the derivative liability, using the Black Scholes model, to be $44,952. Accordingly the Company has recognized a derivative liability in that amount offset by a debt discount. The Company will amortize the debt discount as interest expense over the one year term of the Note.


10


Effective November 15, 2019, the following transactions took place in the Company’s notes payable:

·The Company entered into new promissory notes with two accredited investors under which the Company borrowed a total of $300,000, with such notes maturing in five years, accruing interest at 5% per annum, and being convertible into common stock at the option of the holders, at a conversion price of $0.05 per share. 

·The two holders of outstanding convertible notes payable elected to exercise their existing rights to convert a portion of their notes into shares of common stock, at the stated conversion ratio of $0.13 per share.  The two holders converted a total principal amount of $2,034,760 in notes into a total of 15,652,000 shares of common stock leaving the remaining total principal balance of $165,240 unconverted. 

·The Company entered into an amendment with the holders of existing non-convertible notes in the total principal amount of $732,835 (out of a total of $756,535) whereby such notes will remain outstanding and continue to accrue interest with deferral of the maturity dates being extended for one year or until the Company has raised an additional $500,000 of new equity securities, at which time, the principal and accrued interest shall be converted into common stock at a conversion price of $0.05 per share. 

The Company performed an analysis of both the newly issued convertible notes and the newly amended existing notes, which were formerly non-convertible, to determine whether there was a beneficial conversion feature and noted none.

(6)Stockholders’ Equity

Effective January 13, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada to increase the total authorized shares of common stock of the Company from 200 million shares to 750 million shares and to authorize 100 million shares of “blank check” preferred stock of the Company.

During the quarter ended June 30, 2020, the Company entered into private stock subscription agreements with six separate accredited investors whereby the Company sold a total of 960,000 shares of restricted common stock to these six investors at an offering price of $0.25 per share, resulting in gross proceeds to the Company of $240,000.

Additionally, the Company awarded 1,358,334 shares of restricted common stock to a total of 11 consultants during the quarter ended June 30, 2020 as compensation for services.  Based on the timing of these awards in relation to the private offering of common stock noted above, the Company valued the shares at a price of $0.25 per share, for total non-cash compensation expense of $339,584.

In March 2018, the Board approved the establishment of a new 2018 Stock Option Plan with an authorization for the issuance of up to 1,000,000 shares of common stock. The Plan is designed to provide for future discretionary grants of stock options, stock awards and stock unit awards to key employees and non-employee directors.  The Company has made no issuances under this Plan.

(7)Related Party Transactions

Office services have been provided without charge by a director. Such costs are immaterial to the consolidated financial statements and, accordingly, have not been reflected therein. The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such eventspersons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.


11


(8)Commitments and Contingencies

From time to time in the ordinary course of our business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We currently have occurred.no insurance policies covering such potential losses.



We are not at this time involved in any legal proceedings.



(9)Subsequent Events



Since December 31, 2019 and through the date of this report, the entire global economy has been substantially impacted by the coronavirus pandemic which began in China and has spread to the United States and most other parts of the world. As disclosed in Note 1, the Company has adopted a new business strategy focused on developing potential commercial opportunities which will involve the rapid application of therapeutics using proprietary metered dose inhaler technology that the Company has recently sublicensed from a third party. The range of possible impacts on the Company’s business from the coronavirus pandemic could include: (i) changing demand for the Company’s products; (ii) rising bottlenecks in the Company’s supply chain; and (iii) increasing contraction in the capital markets.  At this time, the Company believes that it is premature to determine the potential impact on the Company’s business prospects from these or any other factors that may be related to the coronavirus pandemic.



In August 2020, the Company entered into private stock subscription agreements with thirty-three separate accredited investors whereby the Company sold a total of 2,404,000 shares of restricted common stock to these investors at an offering price of $0.25 per share, resulting in gross proceeds to the Company of $601,000.










MANAGEMENT'S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS


12



ItemITEM 2. Management'sMANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We make forward-looking statements under the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of OperationsOperations” and in other sections of this Report. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Report.


Forward-Looking InformationYou should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Report to conform our prior statements to actual results or revised expectations, and we do not intend to do so, except as otherwise provided by law.


You should read the matters described in “Risk Factors” and the other cautionary statements made in this Report, as being applicable to all related forward-looking statements wherever they appear in this Report. We cannot assure you that the forward-looking statements in this Report will prove to be accurate and therefore prospective investors are encouraged not to place undue reliance on forward-looking statements. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.

This Quarterly Report on Form 10-Q contains forward-looking statements. When usedinformation should be read in conjunction with the interim unaudited financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, and the words "anticipate," "believe," "estimate," "will," "plan," "seeks," "intend,"audited financial statements and "expect"notes thereto and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in this Quarterly Report on Form 10-Q All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Quarterly Report on Form 10-Q. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Critical Accounting Policies


There have been no material changes to our critical accounting policies and estimates from the information provided in, "Management's“Part II. Other Information - Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations"Operations”, includedcontained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017.2020, filed with the Securities and Exchange Commission on June 29, 2020 (the “Annual Report”).


Results of Operations


Overview of Current Operations


Holly Brothers Pictures, Inc. was incorporatedCertain capitalized terms used below and otherwise defined below, have the meanings given to such terms in the Statefootnotes to our unaudited consolidated financial statements included above under “Part I - Financial Information” - “Item 1. Financial Statements”.

In this Report, we may rely on and refer to information regarding the industries in which we operate in general from market research reports, analyst reports and other publicly available information. Although we believe that this information is reliable, we cannot guarantee the accuracy and completeness of Nevada on February 22, 2013, originally under the name of PowerMedChairs. We consider ourselves to be an emerging growth company under applicable federal securities lawsthis information, and will be subject to reduced public company reporting requirements. From our inception to date, we have generated no revenues, and our operations have been limited to organizational, start-up, and capital formation activities. Our plannot independently verified any of operation is to re-build wheelchairs in disrepair, market our services and sell wheelchairs.it.


On March 26, 2013,Unless the company formed a subsidiary named PowerMedChairs Shareholder Acquisition Corporation. This subsidiary acquired the control block of 25,000,000 shares of Tropical PC, Inc. a dormant Nevada corporation for $10,000 cash. This control block represent 99.2% of the issued and outstanding shares of Tropical PC. After the 25,000,000 shares were acquired by PowerMedChairs, by a Board Resolution, they were cancelled. The remaining shareholders of Tropical PC, representing 210,000 shares exchanged their shares on a one-for-one basis for shares in the subsidiary. When the subsidiary collapsed into PowerMedChairs, each of the subsidiary’s shareholders received a one-for-one share exchange of PowerMedChairs shares. These newly issued shares were issued in the reliance upon the exemption from registration provided by section 4(2) of the Act, on the basis that the transaction does not involve a public offering.







Our Business


Holly Brothers Pictures, Inc. plans to rebuild primarily electric/power wheelchairs in disrepair. Electric wheelchairs are for people who need support for their upper body and who are unable to move a manual chair with their arms and hands. A power chair has a more supportive seat and often a headrest for people who are not able to hold themselves upright. The electric wheelchair consists of a number of mechanical and electric components that need to be replaced every few year. In most cases, it is much more cost effective to repair a broken electric wheelchair than replace the entire unit.


Products and Services


A wheelchair is a chair with wheels, designed to be a replacement for walking. The device comes in variations where it is propelled by motors or by the seated occupant turning the rear wheels by hand. Often there are handles behind the seat for someone else to do the pushing. Wheelchairs are used by people for whom walking is difficult or impossible due to illness (physiological or physical), injury, or disability


Everyday manual wheelchairs come in two major designs-folding or rigid. The rigid chairs, which are increasingly preferred by active users, have permanently welded joints and many fewer moving parts. This reduces the energy required to push the chair by eliminating many points where the chair would flex as it moves. Welding the joints also reduces the overall weight of the chair. Rigid chairs typically feature instant-release rear wheels and backrests that fold down flat, allowing the user to dismantle the chair quickly for storage in a car.


The primary design of a rigid wheelchair is to fit the body of the user. The primary design of a folding wheelchair is to fold. Folding wheelchairs are generally boxy, while rigid wheelchairs conformcontext requires otherwise, references to the shape“Company,” “we,” “us,” “our,” “RTSL”, refer specifically to Rapid Therapeutic Science Laboratories, Inc. and its consolidated subsidiary.

In addition, unless the context otherwise requires and for the purposes of the body. For example, with a rigid chair, one can taper the design to conformthis Report only:

·“Exchange Act” refers to the body shape (large atSecurities Exchange Act of 1934, as amended; 

·“SEC” or the hips, narrow at the knees) which can hold the users’ body in place. Also the aluminum between the knees and footrest can be tapered (wider at the knees, narrow at the feet) holding the feet in place. With a folding chair, you cannot taper it or it would not close completely


Rigid wheelchairs generally have more configurations and adjustments then folding chairs. Most folding wheelchairs have limits in their configurations and adjustments. For example, many folding wheelchairs do not allow for adjusting the angle between the backrest and the seat.


Many rigid models are now made with ultra-light materials such as aircraft aluminum and titanium. Another innovation in rigid chair design is the installation of polymer shock absorbers, which cushion the bumps over which the chair rolls. These shock absorbers may be added“Commission” refers to the front wheels or to the rear wheels, or both. Rigid chairs also have the option for their rear wheels to have a camber. Wheels can have a camber, or tilt, which angles the tops of the wheels in toward the chair. This allows for better propulsion by the user which is desired by long-term users. Sport wheelchairs have large camber angles to improve stability.


An electric-powered wheelchair is a wheelchair that is moved via the means of an electric motor and navigational controls, usually a small joystick mounted on the armrest, rather than manual power. For users who cannot manage a manual joystick, head switches, chin-operated joysticks, sip-and-puff or other specialist controls may allow independent operation of the wheelchair


A power-assisted wheelchair is a recent development that uses the frame & seating of a typical manual chair while replacing the standard rear wheels with wheels that have small battery-powered motors in the hubs. A floating rim design senses the pressure applied by the users push & activates the motors proportionately. This results in the convenience, small size & light-weight of a manual chair while providing motorized assistance for rough/uneven terrain & steep slopes that would otherwise be difficult or impossible to navigate, especially by those with limited upper-body function.



9



We plan to rebuild wheelchairs in disrepair. These wheelchairs can be highly customized for the user's needs. Such customizations may encompass the seat dimensions, height, seat angle (also called seat dump or squeeze), footrests, leg rests, front caster outriggers, adjustable backrests and controls. Additional customizations can include various optional accessories, such as anti-tip bars or wheels, safety belts, adjustable backrests, tilt and/or recline features, extra support for limbs or neck, mounts or carrying devices for crutches, walkers or oxygen tanks, drink holders, and clothing protectors. Based on management’s past experience with A&A Medical Supply in repairing wheelchairs, the time needed to rebuild a wheelchair will take us 5-6 weeks, which includes the time needed to obtain prior approval from the patient’s insurance company. The basic cost to rebuild a wheel chair can be $2,000. If we were to add special features (tilt or recline chair) to the wheelchair, the price could increase by an additional $3,000.


Recent technological advances are improving wheelchairs and its technology. Some wheelchairs incorporate gyroscopic technology and other advances, enabling the chair to balance and run on only two of its four wheels on some surfaces, thus raising the user to a height comparable to a standing person. They can also incorporate stair-climbing and four-wheel-drive feature motorized assists for hand-powered chairs are becoming more available and advanced.


Wheelchair Reimbursement


The company is directly affected by government regulation and reimbursement policies in virtually every State in which the company operates. In the United States Securities and Exchange Commission; and 

·“Securities Act” refers to the growthSecurities Act of health care costs1933, as amended. 


13


Where You Can Find Other Information

We file annual, quarterly, and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC like us at http://www.sec.gov. Copies of documents filed by us with the SEC are also available from us without charge, upon oral or written request to our Secretary, who can be contacted at the address and telephone number set forth on the cover page of this Report.

Overview

Effective November 15, 2019, the Company and TMDI entered into the Agreement granting the Company access to certain technology regarding the RxoidTM MDI inhaler that TMDI has increased at rates in excesslicensed from a third party (see Note 4 to the financial statements included above). In conjunction with execution of the rateAgreement, the Company issued a total of inflation140,000,000 shares of Common Stock to TMDI, resulting in a change in control of the Company.  At the same time, the Company named Donal R. Schmidt, Jr., TMDI’s founder and president, as its Chairman and Chief Executive Officer. The Company commenced its initial business operations under the new business strategy in early 2020.  In order to more closely represent and reflect the new business strategy, the Company changed its name to Rapid Therapeutic Science Laboratories, Inc., effective January 13, 2020.

During the term of the Agreement, the Company is required to reimburse TMDI to the extent that TMDI is required to make any payments to EM3 Methodologies, LLC (“EM3”)(the licensor of the technology), pursuant to the License Agreement between EM3 and TMDI, as a percentageresult of GDPthe Agreement. The Company’s obligation to make such reimbursements to TMDI is conditioned upon TMDI providing the Company with an advance notice requesting such payments, along with an accounting showing the calculations for several decades. A numbersuch payments (see also Note 4 to the financial statements included above).

With execution of efforts to control the federal deficit have impacted reimbursement levels for government sponsored health care programs, and private insurance companies and state Medicaid programs peg their reimbursement levels to Medicare.


Reimbursement guidelinesAgreement, the Company adopted a new business strategy focused on developing potential commercial opportunities in the home health care industrygreater aerosol manufacturing space not limited to cannabinoids. This business strategy will involve the rapid application of therapeutics using the RxoidTM MDI technology that is being sublicensed from TMDI. The market for such products includes, but is not limited to, prospective healthcare providers, pharmacies and other parties such as major retailers and wholesale medical distributors. Finally, the Company will utilize a robust direct marketing campaign on the internet, where legal. Although the sub-license with EM3 is exclusive to manufacturing in the States of Texas, California, Florida and Nevada, RxoidTM or any other aerosol product manufactured by the Company related to the licensed technology may be marketed and produced world-wide on a non-exclusive basis, where legal. Simultaneously, the Company exited from its previous operations in the bitcoin mining business, which had been suspended since the middle of 2018.

Plan of Operations

Since execution of the Agreement with TMDI in November 2019, our plan of operations has been primarily focused on using the proceeds of the convertible notes received in conjunction with the TMDI transaction in order to fund the preliminary activities of marketing and production planning for our licensed aerosol inhaler product line ultimately leading to the initial sales of our new products, beginning in early 2020. In that regard, we have supplemented the proceeds received from the convertible notes issued in November 2019 with the private sales of restricted shares of our common stock to various accredited investors, as well as a substantialrelatively small amount of new convertible note borrowings, to further fund our operations since January 2020.

Novel Coronavirus (COVID-19)

In December 2019, a novel strain of coronavirus, which causes the infectious disease known as COVID-19, was reported in Wuhan, China. The World Health Organization declared COVID-19 a “Public Health Emergency of International Concern” on January 30, 2020 and a global pandemic on March 11, 2020. In March and April, many U.S. states and local jurisdictions began issuing ‘stay-at-home’ orders. As disclosed above, the Company has adopted a new business strategy focused on developing potential commercial opportunities which will involve the rapid application of therapeutics using proprietary metered dose inhaler technology that the Company has recently sublicensed from a third party. The range of possible impacts on the Company’s business from the coronavirus


14


pandemic could include: (i) changing demand for the Company’s products; (ii) rising bottlenecks in the Company’s supply chain; and (iii) increasing contraction in the capital markets. At this time, the Company believes that it is premature to determine the potential impact on the natureCompany’s business prospects from these or any other factors that may be related to the coronavirus pandemic; however, it is possible that Covid-19 and typethe worldwide response thereto, may have a material negative effect on our operations, cash flows and results of equipment an end-user can obtainoperations.

Currently we believe that we have sufficient cash on hand, and thus, affectavailability to raise additional funding, or borrow additional funding, as needed, to support our operations for the product mix, pricingforeseeable future; however, we will continue to evaluate our business operations based on new information as it becomes available and payment patternswill make changes that we consider necessary in light of any new developments regarding the pandemic.

The future impact of COVID-19 on our business and operations is currently unknown. The pandemic is developing rapidly and the full extent to which COVID-19 will ultimately impact us depends on future developments, including the duration and spread of the company’s customers who are medical equipment users. Management believes its technical expertise will allow it to respond to ongoing regulatory reimbursement changes. However, the issues described above will likely continue to have significant impacts on the pricing of the company’s products.


Medicare Wheelchair Reimbursement


Manual wheelchairs are considered "Durable Medical Equipment" under Medicare guidelines. Most of the cost of a wheelchair will be covered under your Original Medicare Part B plan. A wheelchair user will have to pay 20 percent and meet your yearly Part B deductible.


In order for a wheelchair to be covered under Medicare, the requirements are:


·

It must be medically necessary, as determined by a doctor

·

A physician has documented this information for Medicare

·

The patient has a "Certificate of Necessity" (like a prescription)

·

The patient must purchase your wheelchair from a Medicare-approved supplier


Prior Approval


Before the Company can begin work on rebuilding a wheelchair, it must contact the patient’s insurance provider. The insurance provider, based on the age, condition, and cost to repair the wheelchair will make a decision to approve the repairs. In many cases, where the power wheelchair is more than five (5) years old, the insurance carrier will not approve the repairs and recommend the patient purchases a new wheelchair.





Marketing Strategy


Our sole officer/director is also CEO of A&A Medical Supply, LLC, based at the same address as our company in Ohio. A&A Medical Supply, LLC is a growing medical supply company that services in the medical supply needs to patients in the Cleveland, OH area. PowerMedChairs entered into a separate Service Agreement with A&A Medical Supply to rebuild the wheelchairs brought into its shop for repairs. Currently, A&A Medical Supply receives approximately thirty (30) broken wheelchairs per month. There are no assurances, this number of repairs will remain at this level.


Additionally, the Company plans to market its services to doctors, therapists, home health care agencies in the Ohio, Eastern Indiana and Northern Kentucky areas. It is these health care providers that are the first to recognize a wheelchair in disrepair. The marketing to these individuals, will take place by sending them sales brochure on what the Company can do, and speaking directly with these providers.


If the Company can move its business forward, management would consider building and marketing its own branded wheelchair.


COMPETITION


We may not have the resources to compete with our existing competitors or with any new competitors. We intend to compete with many other competitors who perform wheelchair repairs, all of which have significantly greater personnel, financial, and managerial resources than we do. This competition from other companies with greater resources and reputations may result in our failure to maintain or expand our business.


Moreover, as the demand for wheelchairs increases, new companies may enter the market and the influx of added competition will pose an increased risk to our Company. Increased competition may lead to price wars, which would harm us since we would be unable to compete with companies with greater resources. In addition, increased competition and increased demand may create a stress on the wheelchair manufacturers, output capabilities, which may lead to increased prices, which would also harm our ability to compete in the wheelchair market.


INTELLECTUAL PROPERTY


We rely or plan to rely on a combination of trademark, copyright, trade secret and patent laws in the United States,virus, as well as confidentiality procedures and contractual provisions to protect our wheelchair proprietary repair methodologies and anypotential seasonality of new wheelchair brand we might develop in the future. We currently have no pending patents, nor trademarks.outbreaks


From time to time, we expect that we may encounter disputes over rights and obligations concerning intellectual property. Also, the efforts management has taken to protect its proprietary rights may not be sufficient or effective. Any significant impairment of its intellectual property rights could harm the existing business, the brand and reputation, and the ability of the business to compete on a going forward basis. Also, protecting our intellectual property rights could be costly and time consuming.


Employees


We currently has no employees, our CEO performs all duties related to the operations of this business. We also plan to utilize additional independent contractors on a part-time/as needed basis.





11



Property


Our corporate headquarters are located at: 8221 E. Washington Street, Chagrin Falls, OH 44023. We do not own any real property. Management believes that its current facilities are adequate for its needs through the next twelve months, and that, should it be needed, suitable additional space will be available to accommodate expansion of the Company's operations on commercially reasonable terms, although there can be no assurance in this regard.


Results of Operations

The following discussion reflects the Company’s revenues and expenses for the three month periods ended June 30, 2020 and nine2019, as reported in our consolidated financial statements included in Item 1.

Three months ended December 31, 2017 and 2016June 30, 2020 versus three months ended June 30, 2019


During the three month period ended December 31, 2017, theRevenues - The Company did not generate any revenues. In addition, thecommenced sales of its inhaler products to customers in January 2020.  The Company does not expecthas two different sales channels as follows:

Wholesale - designed to generate anycapture fairly large, but sporadic, orders received from wholesale customers, often for substantial quantities with relatively high profit for the next twelve months.margins. 


ForRetail - designed to capture a high volume of small orders received from retail customers through an online portal, with significantly lower profit margins. 

The revenues from such sales in the three months ending December 31, 2017, we experienced a net lossended June 30, 2020, consisting mostly of $5,399, astwo large wholesale orders, were $129,287 compared to a net loss of $2,800 for the same period last year. The net losszero for the three months ending December 31, 2017 was attributedended June 30, 2019.  Revenues from sales of the Company’s inhaler products, under both sales channels, are expected to $5,399 in general & administrative expenses, as compared to $2,800 in general & administrative expenses for the same period last year.


For the nine months ending December 31, 2017, we experienced a net loss of $16,713, as compared to a net loss of $12,846 for the same period last year. The net loss for the nine months ending December 31, 2017 was attributed to $16,713 in general & administrative expenses, as compared to $12,846 in general & administrative expenses for the same period last year.


Revenues


The Company has generated no revenues since its inception. As of December 31, 2017, the Company had an accumulated deficit of $(91,793). There can be no assurances that the Company can achieve or sustain profitability or that the Company's operating losses will notgradually increase in the future.


PlanCost of OperationGoods Sold - Cost of goods sold for the three months ended June 30, 2020 were $18,556 compared to zero for the three months ended June 30, 2019. The cost of goods sold in the 2020 period reflected the cost of procuring inhalers and related products and supplies for resale and resulted in a gross profit of approximately 85%, reflecting a relatively large portion of sales to higher profit wholesale customers.


General and Administrative Expense - General and administrative expenses for the three months ended June 30, 2020 were $629,510 compared to $22,974 for the three months ended June 30, 2029. This increase was due to the higher level of overhead costs following the Company’s recent adoption of a new business strategy focused on developing potential commercial opportunities which will involve the rapid application of therapeutics using the RxoidTM MDI technology that is being sublicensed from TMDI. Included in general and administrative expenses were non-cash stock compensation expenses for restricted stock grants to various consultants in the amounts of $339,584 and $10,750, respectively.

Amortization Expense - Amortization expense for the three months ended June 30, 2020 was $25,000 compared to zero for the three months ended June 30, 2019. This increase was due to the Company’s quarterly amortization of its obligation to reimburse TMDI in the amount of $200,000 for a license fee owed by TMDI to a third party licensor covering the first two years of the sublicense agreement.

Interest Expense - Interest expense for the three months ended June 30, 2020 was $22,601 versus $46,099 for the three months ended June 30, 2019. This decrease was due to lower level of outstanding borrowings following the conversion of certain convertible notes payable into common stock in November 2019.


15


Liquidity and Capital Resources

Operating activities.  Net cash used in operating activities for the three months ended June 30, 2020 was $215,092 compared to $6,868 for the three months ended June 30, 2019. This net increase was largely due to the higher level of overhead costs following the Company’s recent adoption of a new business strategy in early 2020, as further noted above.

Financing activities. Net cash provided by financing activities was $292,000 for the three months ended June 30, 2020 compared to $8,000 for the three months ended June 30, 2019. This increase was largely due to the private sales of common stock in the amount of $240,000 and the issuance of convertible notes payable in the amount of $52,000 (net of transaction cost of $3,000).

Prior to the three months ended June 30, 2019, the Company entered into an equity subscription agreement with a third party investor in February 2020, whereby the Company agreed to sell the third party 640,000 shares of restricted common stock and a large number of common stock purchase warrants, in exchange for a cash payment to the Company of $90,000, and the performance of certain other obligations. The Company’s planterms and conditions of operation isthis memorandum agreement were subject to re-build wheelchairs in disrepair, market its services and sell wheelchairs. Asthe negotiation of December 31, 2017, we had $5,382 cash on hand. We will apply any proceedsa definitive agreement between the parties. To date, the parties have not reached such definitive agreement. Accordingly, the Company has recorded the $90,000 payment received from future revenues to help cover our expenditures. At this time, management does not anticipatethe third party as a current liability with the expectation that it will eventually either be requiredconverted into some form of equity, converted to seek outside fundinga term loan, or refunded to keep its business operational for the next twelve months. However, doesthird party.

We have not preclude managementgenerated a net profit from seeking funding in the future.


If and when the time comes that we seek funding, we plan to rely on equity sales of our common sharesinhaler products beginning in orderearly 2020. Additionally, we had a working capital deficit of $1.3 million as of June 30, 2020. Accordingly, we will need to continueraise additional capital to fund our businessfuture operations. And,Until such time that we would havecan generate substantial net profit from operations, if ever, we expect to issuefinance our operating activities through a combination of equity offerings and debt financings and we may seek to raise additional capital through strategic collaborations.

However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our operations. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic arrangement with a third party. Issuances of additional shares will result inconsiderations, which may cause dilution to our existing shareholders. There is no assurancestockholders.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has generated limited revenues and has suffered recurring losses totaling $4,167,799 since inception. These factors, among others, indicate that we will achieve any of additional sales of our equity securities or other financing to fund our business operations. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.


Future funding could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to goodwill and other intangible assets, which could materially adversely affect the Company's business, results of operations and financial condition. Any future acquisitions of other businesses, technologies, services or product(s) might require the Company to obtain additional equity or debt financing, which might notmay be available on terms favorable to the Company, or at all, and such financing, if available, might be dilutive.





12



Going Concern


Our independent auditors included an explanatory paragraph in their report on the March 31, 2017 audited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors. Our abilityunable to continue as a going concern is contingent uponfor a reasonable period of time. The consolidated financial statements do not contain any adjustments to reflect the successful completionpossible future effects on the classification of additional financing arrangementsassets or the amounts and our ability to achieve and maintain profitable operations.


Therefore, management plans to raise equity capital to finance the operating and capital requirementsclassification of the Company. Whileliabilities that may result should the Company is devoting its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt about the Company's abilityunable to continue as a going concern.


Summary of any product research and development that we will perform for the term of our plan of operation.


We do not anticipate performing any product research and development under our current plan of operation.


Expected purchase or sale of plant and significant equipment.


We do not anticipate the purchase or sale of any plant or significant equipment; as such items are not required by us at this time.


Significant changes in the number of employees.


As of December 31, 2017, we did not have any employees. We are dependent upon our two officers for our future business development. As our operations expand we anticipate the need to hire additional employees, consultants and professionals; however, the exact number is not quantifiable at this time.


Liquidity and Capital Resources


The Company is authorized to issue 200,000,000 shares of its $0.001 par value common stock. As of December 31, 2017, the Company has 2,865,172 shares of common stock issued and outstanding.


The Company has limited financial resources available, which has had an adverse impact on the Company's liquidity, activities and operations. In order for the Company to remain a Going Concern it will need to find additional capital or generate revenues. Additional working capital may be sought through additional debt or equity private placements, additional notes payable to banks or related parties (officers, directors or stockholders),or from other available funding sources at market rates of interest, or a combination of these. The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought. No assurances can be given that any necessary financing can be obtained on terms favorable to the Company, or at all.


Management believes the Company has sufficient cash assets to fund its operations and keep the Company fully reporting for the next twelve (12) months, without seeking additional outside funding.


Off-Balance Sheet Arrangements


We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.



13



Critical Accounting Policies and Estimates


Revenue Recognition: We recognize revenue from product sales once allOur discussion and analysis of the following criteria for revenue recognitionour financial condition and results of operations are based on consolidated financial statements which have been met: pervasive evidence that an agreement exists;prepared in accordance with generally accepted accounting principles in the services have been rendered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured.


New Accounting Standards


United States. The Company's management has evaluated all the recently issued accounting pronouncements through the filing datepreparation of these financial statements requires us to make estimates and does notjudgments that affect the reported amounts of assets, liabilities, revenues and expenses.  We believe that anycertain accounting policies affect our more significant judgments and estimates used in the preparation of these pronouncements will haveour consolidated financial statements.  See our Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the SEC on June 29, 2020, for a material impact on the Company's financial positionfurther description of our critical accounting policies and results of operations.estimates.


16



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Information for this Item 3. Quantitativeis not required as the Registrant is a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act.

ITEM 4. CONTROLS AND PROCEDURES

(a) Disclosure controls and Qualitative Disclosures about Market Risk.procedures


Not applicable.


Item 4T. ControlsWe have established and Procedures


Evaluationmaintain a system of Disclosure Controls and Procedures


Our disclosure controls and procedures as defined in Rule 13a-15(e) and15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"),that are designed to ensureprovide reasonable assurance that information required to be disclosed in our reports filed or submitted underwith the Securities and Exchange Commission pursuant to the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms adopted byof the SEC,Commission and that such information is accumulated and communicated to our management, including theour Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), to allow timely decisions regarding required disclosures.


Management, with the participationAs of theJune 30, 2020, our Chief Executive Officer and the Chief Financial Officer has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act).  Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of the end of the period covered by this report. Based on such evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, our disclosure controls and procedures were not effective. Our disclosure controls and proceduresQuarterly Report were not effective because of the "material weaknesses" described below under "Management's report on internal control over financial reporting," which are in the processa lack of being remediatedsegregation of duties, as described below under "Management Plan to Remediate Material Weaknesses."


Management'sin Item 9A. of our Annual Report on Internal Control over Financial Reporting


Our management is responsibleForm 10-K for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting,the year ended March 31, 2020, which we view as defined in rules promulgated under the Exchange Act, is a process designed by, or under the supervisionan integral part of our Chief Executive Officerdisclosure controls and Chief Financial Officer and affected by our Boardprocedures.

The lack of Directors, management and other personnel to provide reasonable assurance regarding their liabilitysegregation of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:


·

pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

·

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our Board of Directors; and

·

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could haveduties referenced above represents a material effect on our financial statements



14



Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.


Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2017. In making its assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material weaknessesweakness in our internal controls over financial reporting.  As a result, our internal control over financial reporting was not effective as of December 31, 2017.


A "material weakness" is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting suchNotwithstanding this weakness, management believes that there is a reasonable possibility that a material misstatement of a company's annual or interimthe consolidated financial statements will not be prevented or detected on a timely basis by the company's internal controls. As a result of management's review of the investigation issues and results, and other internal reviews and evaluations that were completed after the end of quarter related to the preparation of management'sincluded in this report on internal controls overfairly present, in all material respects, our consolidated financial reporting required for this quarterly report on Form 10-Q, management concluded that we had material weaknesses in our control environment and financial reporting process consisting of the following:


1.

lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;


2.

insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements;


We do not believe the material weaknesses described above caused any meaningful or significant misreporting of our financial conditionposition and results of operations as of and for the periodquarter ended December 31, 2017. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.June 30, 2020.


Management Plan to Remediate Material Weaknesses


Management is pursuing the implementation of corrective measures to address the material weaknesses described below. In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:


We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. We plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.




We believe the remediation measures described above will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address control deficiencies or determine to modify, or in appropriate circumstances not to complete, certain of the remediation measures described above.


Changes in Internal Control over Financial Reporting


There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act)during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


This quarterly report does not include an attestation report of the Corporation's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Corporation's registered public accounting firm pursuant to temporary rules of the SEC that permit the Corporation to provide only the management's report in this quarterly report.


(b) Changes in internal controls over financial reporting


There was no change in our internal controls over financial reporting that occurred during the period covered by this reportquarter ended June 30, 2020, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.


















17















PART II. OTHER INFORMATION


ItemITEM 1. Legal ProceedingsLEGAL PROCEEDINGS


From time to time,Although we may, become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time, that may harmbe involved in litigation and claims arising out of our business.


Mark DeStefano v. PowerMedChairs, A&A Medical Supply, LLC, Anushavan Yeranossian, and Anton Yeranossian, filed as Eighth Judicial District Court Case No. A-17-750526-C, pursuantoperations in the normal course of business, we are not currently a party to Stipulation, was Dismissed with Prejudice by Orderany material legal proceeding. In addition, we are not aware of the Court on November 22, 2017.


Ed DeStefano, Mark DeStefano and T.J. Jesky v. Anton Yeranossian and PowerMedChairs, filed as Eighth Judicial District Court Case No. A-17-750604-C, pursuantany material legal or governmental proceedings against us, or contemplated to Stipulation, was Dismissed with Prejudice by Order of the Court on December 4, 2017.be brought against us.


ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A. Risk Factors


See Risk Factors set forth in1A of the Company'sCompany’s Annual Report on Form 10-K for the fiscal year ended March 31, 20172020, filed with the Commission on June 29, 2020 (the “Form 10-K”), under the heading “Risk Factors”, and investors should review the discussionrisks provided in Item 1, above,the Form 10-K, which are incorporated by reference herein, prior to making an investment in the Company. The business, financial condition and operating results of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in the Form 10-K for the year ended March 31, 2020, under "Liquidity“Risk Factors”, any one or more of which could, directly or indirectly, cause the Company’s actual financial condition and Capital Resources."operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition, operating results and stock price.


ItemITEM 2. Unregistered SalesUNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the quarter ended June 30, 2020, the Company entered into private stock subscription agreements with six separate accredited investors whereby the Company sold a total of Equity Securities and Use960,000 shares of Proceeds


On January 20, 2016, $10,000 was loanedrestricted common stock to these six investors at an offering price of $0.25 per share, resulting in gross proceeds to the Company by a shareholder. An additional $10,000 was loaned on August 22, 2016, $10,000 on March 24, 2017, $5,000 on July 13, 2017, $5,000 on October 26, 2017 and $5,000 on December 16, 2017. These loans bore no interest and were due upon demand. Asof $240,000.

Additionally, the Company lacked adequate cashawarded 1,358,334 shares of restricted common stock to repaya total of 11 consultants during the quarter ended June 30, 2020 as compensation for services.  Based on the timing of these debts, it was mutually agreedawards in relation to the private offering of common stock noted above, the Company valued the shares at a price of $0.25 per share, for total non-cash compensation expense of $339,584.

Effective June 30, 2020, the Company and Power Up Lending Group, Ltd. (the “Buyer”) entered into a Securities Purchase Agreement (the “Agreement”) with respect to a Convertible Promissory Note (the “Note”) issued by the Company to the Buyer in the amount of $55,000. The Note has a maturity date of one year after the date of issuance and bears interest at a rate of 12% per annum, which is not due until maturity. At the option of the Buyer, the Note may be converted into shares of the Company’s common stock beginning one hundred eighty (180) days following the date of issuance. Under this option, the conversion price is subject to a discount of 42%, based on December 18, 2017 to settle this $45,000 debt in exchangethe average of the three (3) lowest closing bid prices for the issuancecommon stock during the prior fifteen (15) trading day period. The Buyer will be limited to convert no more than 4.99% of 155,172 restricted unregisteredthe issued and outstanding common stock at time of conversion at any one time.

In August 2020, the Company entered into private stock subscription agreements with thirty-three separate accredited investors whereby the Company sold a total of 2,404,000 shares of restricted common stock.stock to these investors at an offering price of $0.25 per share, resulting in gross proceeds to the Company of $601,000.

We claim an exemption from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act for such issuances, since the foregoing issuances did not involve a public offering, the recipients were (a) an “accredited investor”; and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Securities Act. The securities are subject to transfer restrictions, and the certificates evidencing the securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom. The securities were not registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.


18



ItemITEM 3. Defaults Upon Senior SecuritiesDEFAULTS UPON SENIOR SECURITIES


None.


ItemITEM 4. Submission of Matters to a Vote of Security HoldersMINE SAFETY DISCLOSURES


None.


ItemITEM 5. Other InformationOTHER INFORMATION


None.













Item

ITEM 6. ExhibitsEXHIBITS


Exhibit No.

Incorporated by reference

Exhibit

Exhibit Description

Filed

herewith

Form

Period

Ending

Exhibit

Filing

Date

��

3.110.1

ArticlesSecurities Purchase Agreement between Rapid Therapeutic Science Laboratories, Inc. and Power Up Lending Group, Ltd., dated as of Incorporation,June 30, 2020 (filed as currently in effect

S-1

3.1

05/23/2013Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2020, and incorporated herein by reference)(File No. 000-55018)

3.210.2

Bylaws, as currently in effect

S-1

3.1

05/23/2013

10.1

Service Agreement between PowerMedChairs and A&A Medical Supply, LLC dated May 1, 2013

S-1

10.1

05/23/2013Form of Subscription Agreement*

31.1

Certification of PrincipalChief Executive Officer and Principal Financial Officerpursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.2002*

31.2

X

Certification of Chief Financial Officer pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1

Certification of PrincipalChief Executive Officer and Principalpursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to sectionSection 906 of the Sarbanes-Oxley Act of 2002.2002**

X

 

 

101.INS

XBRL Instance Document*

101.SCH

XBRL Taxonomy Extension Schema Document*

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document*

101.LAB

XBRL Taxonomy Extension Label Linkbase Document*

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document*

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document*



* Filed herewith.


** Furnished herewith.












19



SIGNATURE

















SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrantregistrant has duly caused this report to be signed on its behalf by the undersigned, hereuntothereunto duly authorized.



RAPID THERAPEUTIC SCIENCE

LABORATORIES, INC.

 

Holly Brothers Pictures, Inc.

Registrant

/s/ Donal R. Schmidt, Jr.

Donal R. Schmidt, Jr.

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Date: January 23, 2018

/s/ Anton YeranossianD. Hughes Watler, Jr.

 

Name: Anton YeranossianD. Hughes Watler, Jr.

 

Its: Principal Executive Officer

PrincipalChief Financial Officer

(Principal Financial/Accounting OfficerOfficer)

August 13, 2020
































20






19